Detoxification using nanoparticles
The present invention relates treatments of a toxin in a subject. The toxin at least partially effects its toxicity in the subject via binding to a target cell of the subject. The present invention provides for methods, combinations and pharmaceutical compositions for decreasing or neutralizing the effect of a toxin in a subject, using, inter alia, an effective amount of a nanoparticle comprising an inner core comprising a non-cellular material, and an outer surface comprising a cellular membrane derived from a source cell. Exemplary toxins include acetylcholinesterase (AChE) inhibitors such as organophosphate poisoning.
1. A method for decreasing or neutralizing the effect of a toxin in a subject, which method comprises administering, to a subject in need, or to cells of said subject, an effective amount of a nanoparticle comprising a) an inner core comprising a non-cellular material, and b) an outer surface comprising a plasma membrane derived from a source red blood cell,
wherein said toxin is an organophosphate acetylcholinesterase (AchE) inhibitor that binds to AchE on said plasma membrane of said source red blood cell, and said method is used to decrease or neutralize the effect of said toxin in said subject by at least 50% compared to a comparable untreated subject or to said subject at an untreated stage.
2. The method of claim 1 , which is used for decreasing the effect of a toxin in a subject.
3. The method of claim 1 , wherein the inner core comprises a polymeric particle core.
4. The method of claim 1 , wherein the inner core comprises a biocompatible or a synthetic material selected from the group consisting of poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL), polylysine, and polyglutamic acid.
5. The method of claim 1 , wherein the inner core supports the outer surface.
6. The method of claim 1 , wherein the nanoparticle further comprises a releasable cargo.
7. The method of claim 1 , wherein the nanoparticle substantially lacks hemoglobin.
8. The method of claim 1 , wherein the nanoparticle substantially maintains natural structural integrity or activity of the plasma membrane derived from a source red blood cell or the constituents of the plasma membrane derived from a red blood source cell.
9. The method of claim 1 , wherein the nanoparticle is biocompatible or biodegradable.
10. The method of claim 1 , wherein the inner core of the nanoparticle comprises PLGA.
11. The method of claim 1 , wherein the nanoparticle substantially lacks immunogenicity to the subject.
12. The method of claim 11 , wherein the plasma membrane is derived from a source red blood cell from the same species of the subject.
13. The method of claim 1 , wherein the toxin binds to the cells of said subject and the source red blood cell via the same mechanism.
14. The method of claim 1 , wherein the source red blood cell and the cells of said subject to which the nanoparticle is administered are two different types of cells.
15. The method of claim 1 , which further comprises assessing efficacy of the nanoparticle and/or the another active ingredient in decreasing or neutralizing the effect of a toxin in the subject.